

## **HBV FORUM 5**



## Wednesday, April 10th, 2019 Messe Wien Exhibition Congress Center Vienna, Austria

## **DRAFT AGENDA**

Harv Forum 5 Opening Forum Moderator: Veronica Miller, The Forum for Collaborative Research  Welcome and Introduction Ryan Anderson, The Forum for Collaborative Research Harry Janssen, Toronto Centre for Liver Disease, University Health Network Anuj Gagar, Gilead  Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg Clinical Challenges in the Development of HDV Infection Heiner Wederneyer, Essen University Hospital Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wederneyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Update Marion Peters, University of California, San Francisco Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  ### Signal Anderson, The Forum for Collaborative Research  #### Signal Products Agency  ### Signal Products Agency  #	12:30	Light Lunch & Registration
Forum Moderator: Veronica Miller, The Forum for Collaborative Research Welcome and Introduction Ryan Anderson, The Forum for Collaborative Research Harry Janssen, Toronto Centre for Liver Disease, University Health Network Anul Gaggar, Gilead 1:40 Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Hospital Gabriel Westman, Swedish Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Marion Peters, University of California, San Francisco Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  Break  Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Masuviel, Janssen Pharmaceuticals Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BIArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su		
1:30 Welcome and Introduction Ryan Anderson, The Forum for Collaborative Research Harry Janssen, Toronto Centre for Liver Disease, University Health Network Anuj Gaggar, Gilead  1:40 Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  1:45 HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Clenn, Stanford University Medical Center Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Hospital Gabriel Westman, Swedish Medical Products Agency Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Update Marion Peters, University of California, San Francisco Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BIArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Wrap Up	1.50	
Ryan Anderson, The Forum for Collaborative Research Harry Janssen, Toronto Centre for Liver Disease, University Health Network Anuj Gaggar, Gilead  1:40 Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  1:45 HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  Break  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Wrap Up Veronica Miller, The Forum for Collaborative Research	1.30	
Harry Janssen, Toronto Centre for Liver Disease, University Health Network Anuj Caggar, Gilead  1:40 Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  2:15 Panel Discussion  Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates  3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  Association between HBSAQ Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Wrap Up Veronica Miller, The Forum for Collaborative	1.50	
Anuj Gaggar, Gilead  Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  1:45 HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BiArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Veronica Miller, The Forum for Collaborative Research		
1:40 Session I: Insights and Challenges in Drug Development for Treating Hepatitis Delta Session Co-Moderator: Marion Peters, University of California, San Francisco  1:45 HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  2:16 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Update Marion Peters, University of California, San Francisco  3:00 Session II: HBV Forum Working Group Update Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  1:20 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauriel, Janssen Pharmaceuticals  1:21 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  3:22 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:25 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchhotz, Federal Institute for Drugs and Medical Devices (BiArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation		
Session Co-Moderator: Marion Peters, University of California, San Francisco  HDV Therapy - Relevant Recent Findings and Suggested Endpoints  Jeffrey Glenn, Stanford University Medical Center  Clinical Challenges in the Development of HDV Infection  Heiner Wedemeyer, Essen University Hospital  2:15 Panel Discussion  Eric Donaldson, U.S. Food and Drug Administration  Jeffrey Glenn, Stanford University Medical Center  Stephan Urban, University Hospital Heidelberg  Heiner Wedemeyer, Essen University Hospital  Jeffrey Glenn, Stanford University Medical Center  Stephan Urban, University Hospital Heidelberg  Heiner Wedemeyer, Essen University Hospital  Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Update  Marion Peters, University of California, San Francisco  3:10 Review and Meta-Analysis  Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:20 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel  Maria Beumont-Mauviel, Janssen Pharmaceuticals  Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel  Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update  Sara Ferrando-Martinez, AstraZeneca  4:40 Esseion III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection  Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion  Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BiArM)  Russell Fleischer, U.S. Food and Drug Administration  Harry Janssen, Toronto Centre for Liver Disease, University Health Network  Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Veronica Miller, The Forum for Collaborative Research	1.40	
1:45 HDV Therapy - Relevant Recent Findings and Suggested Endpoints Jeffrey Glenn, Stanford University Medical Center  1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  2:15 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Marion Peters, University of California, San Francisco  3:10 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Sesociation between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation Wrap Up Veronica Miller, The Forum for Collaborative Research	1.40	
Jeffrey Glenn, Stanford University Medical Center  Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg  Linical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates  3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:33 Break  1:40 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  1:40 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BIArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation Wrap Up Veronica Miller, The Forum for Collaborative Research	1.45	
1:55 Molecular Insights into the Synergisms between IFN and the Entry Inhibitor Myrcludex B Stephan Urban, University Hospital Heidelberg Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Weronica Miller, The Forum for Collaborative Research	1.45	.,
Stephan Urban, University Hospital Heidelberg  Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital  2:15 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates  3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Veronica Miller, The Forum for Collaborative Research	1.55	
2:05 Clinical Challenges in the Development of HDV Infection Heiner Wedemeyer, Essen University Hospital 2:15 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency 3:00 Session II: HBV Forum Working Group Updates 3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco 3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research 3:30 Break 4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca 4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation Veronica Miller, The Forum for Collaborative Research	1.55	
Heiner Wedemeyer, Essen University Hospital  2:15 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates 3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Wrap Up Veronica Miller, The Forum for Collaborative Research	2:05	
2:15 Panel Discussion Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates 3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Veronica Miller, The Forum for Collaborative Research	2.05	
Eric Donaldson, U.S. Food and Drug Administration Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Patients with Chronic HBV Infection Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  Veronica Miller, The Forum for Collaborative Research	2.15	
Jeffrey Glenn, Stanford University Medical Center Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	2.13	· ·····
Stephan Urban, University Hospital Heidelberg Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates 3:00 Surrogate Endpoints Working Group Updates Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
Heiner Wedemeyer, Essen University Hospital Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates  3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
Gabriel Westman, Swedish Medical Products Agency  3:00 Session II: HBV Forum Working Group Updates  3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
3:00 Session II: HBV Forum Working Group Update  3:00 Surrogate Endpoints Working Group Update  Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
3:00 Surrogate Endpoints Working Group Update Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	3.00	
Marion Peters, University of California, San Francisco  3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  3:30 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
3:10 Association between HBsAg Loss and Long-term Clinical Outcome in Chronic Hepatitis B: A Systematic Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	5.00	
Review and Meta-Analysis Ryan Anderson, The Forum for Collaborative Research  3:30 Break  4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  5ession III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
3:30 Break 4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals 4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca 4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals 4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation 5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	3:10	
<ul> <li>4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals</li> <li>4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca</li> <li>4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals</li> <li>4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation</li> <li>5:55 Wrap Up</li> <li>Veronica Miller, The Forum for Collaborative Research</li> </ul>		·
<ul> <li>4:00 Liver Safety Assessment in Chronic Hepatitis B Drug Development: Recommendations from an Expert Panel Maria Beumont-Mauviel, Janssen Pharmaceuticals</li> <li>4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca</li> <li>4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals</li> <li>4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation</li> <li>5:55 Wrap Up</li> <li>Veronica Miller, The Forum for Collaborative Research</li> </ul>	3:30	
Maria Beumont-Mauviel, Janssen Pharmaceuticals  4:20 Immune Monitoring Working Group Update Sara Ferrando-Martinez, AstraZeneca  4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		
Sara Ferrando-Martinez, AstraZeneca  4:40  Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45  Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55  Wrap Up  Veronica Miller, The Forum for Collaborative Research		
4:40 Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals 4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation 5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	4:20	
Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		Sara Ferrando-Martinez, AstraZeneca
Patients with Chronic HBV Infection Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals  4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	4.40	Session III: Data Interpretations from Trials Stopping Long-Term Treatment with Nucleos(t)ide Analogues in
4:45 Expert Perspectives, Relevant Recent Findings, and Panel Discussion Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	4:40	
Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM) Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		Session Co-Moderator: Bruce Given, Arrowhead Pharmaceuticals
Russell Fleischer, U.S. Food and Drug Administration Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research	4:45	Expert Perspectives, Relevant Recent Findings, and Panel Discussion
Harry Janssen, Toronto Centre for Liver Disease, University Health Network Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up Veronica Miller, The Forum for Collaborative Research		Stephanie Buchholz, Federal Institute for Drugs and Medical Devices (BfArM)
Su Wang, World Hepatitis Alliance, Hepatitis B Foundation  5:55 Wrap Up  Veronica Miller, The Forum for Collaborative Research		Russell Fleischer, U.S. Food and Drug Administration
5:55 <b>Wrap Up</b> Veronica Miller, <i>The Forum for Collaborative Research</i>		Harry Janssen, Toronto Centre for Liver Disease, University Health Network
Veronica Miller, The Forum for Collaborative Research		Su Wang, World Hepatitis Alliance, Hepatitis B Foundation
	5:55	Wrap Up
6:00 Adjourn and Evening Networking Reception		Veronica Miller, The Forum for Collaborative Research
	6:00	Adjourn and Evening Networking Reception